BioPharma Global

PRESS RELEASE: Pace® Life Sciences acquired BioPharma Global!

Read more about this exciting news here:
https://www.pacelabs.com/company/news-and-insights/life-sciences/pace-life-sciences-acquires-biopharma-global-expanding-fda-regulatory-affairs-strategy-and-consulting-capabilities-to-the-biotechnology-and-pharmaceutical-markets/

BridgeBio bounces back? Phase 2 readout provides hope for approval of drug to rebalance calcium levels

Read more: https://www.biopharmaglobal.com/2022/08/29/bridgebio-bounces-back-phase-2-readout-provides-hope-for-approval-of-drug-to-rebalance-calcium-levels/

BridgeBio bounces back? Phase 2 readout provides hope for approval of drug to rebalance calcium levels After a series of unfortunate events for BridgeBio Pharma, the biotech may be on a new upward trajectory as it unveiled positive data from 13 patients taking a drug to treat low calcium levels.

This Week's Rare Disease Highlight is Netherton Syndrome

Read more: https://www.biopharmaglobal.com/2022/08/18/rare-disease-highlight-netherton-syndrome/

Rare Disease Highlight: Netherton Syndrome - BioPharma Global Netherton syndrome (NS), also referred to as bamboo hair syndrome, is a rare and severe genetic skin disorder [1-3]. The disease is characterized by chronic ichthyosiform erythroderma (a condition of fine white and red scales across the entire body), atopy (a genetic tendency to develop allergic dis...